Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


March 26, 2015 3:47 PM ET

Biotechnology

Company Overview of Asterand Bioscience, Inc.

Company Overview

Asterand Bioscience, Inc. develops technology and application solutions that provide researchers the tools to investigate and understand cellular reprogramming worldwide. It provides a set of tools for generating iPS cells, as well as cell lines, media, differentiation, rabbit anti-mouse/human, cytokines/proteins, matrices, reprogramming systems, transfection reagents, small molecules, and antibodies; and iPS cell services, training courses, and video protocols. The company serves reprogramming, self-renewal, and differentiation applications. Asterand Bioscience, Inc. was formerly known as Stemgent, Inc. and changed its name to Asterand Bioscience, Inc. in October 2014. The company was incor...

51 Moulton Street

Cambridge, MA 02138

United States

Founded in 2007

Phone:

617-245-0000

Fax:

617-494-0398

Key Executives for Asterand Bioscience, Inc.

Executive Chairman
Age: 53
Chief Financial Officer
Chief Operating Officer and Executive Vice President
Chief Commercial Officer
Vice President
Compensation as of Fiscal Year 2014.

Asterand Bioscience, Inc. Key Developments

Stemgent, Inc. and Transposagen Biopharmaceuticals Inc. Enters into Partnership Agreement for Development of Genetically Engineered Induced Pluripotent Stem Cells Services for Pharmaceutical, Biotechnology, Academic and Government Organizations

Stemgent, Inc. and Transposagen Biopharmaceuticals Inc. announced that they have entered into a partnership agreement enabling the development of genetically engineered induced pluripotent stem cells (iPSC) services for pharmaceutical, biotechnology, academic and government organizations. The non-exclusive agreement combines Stemgent's industry-recognized expertise in RNA reprogramming with Transposagen's unique genome editing capabilities providing researchers with the convenience of a single point of contact for customer research or disease model systems using patient-specific iPS cells. The newly created service provides customers with a beginning to end solution, starting with Stemgent's expertise in primary cell establishment and iPS cell generation, through genetic manipulation using Transposagen's diverse methods, and ending with a validated cell line that is capable of appropriate differentiation to cardiomyocytes, neurons or hepatocytes.

Asterand Bioscience Seeks Acquisitions

Asterand Bioscience, Inc. (Stemgent Inc.) is seeking acquisitions. John Canepa, Chief Financial Officer of Asterand Bioscience, said, "We'll now be looking at acquisitions. We're strategizing that now. There's an opportunity to grow the business here."

Similar Private Companies By Industry

Company Name Region
Angiomics, Inc. United States
Intralytix, Inc. United States
Advanced Inhalation Research, Inc. United States
Adnexus Therapeutics, Inc. United States
MuciMed, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
September 8, 2014
Stemgent, Inc., Induced Pluripotent Stem Cells Business
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Asterand Bioscience, Inc., please visit www.stemgent.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.